Aclarion, Inc. (ACON) vs GT Biopharma, Inc. (GTBP)
A side-by-side comparison of Aclarion, Inc. and GT Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACON
Aclarion, Inc.
$2.31HealthcareDelayed quote: Oct 6, 2026, 11:58 AM EDT
GTBP
GT Biopharma, Inc.
$6.28HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — ACON vs GTBP
growth of $100 · dividends reinvested · last 4yACON -100.0% (-95.1%/yr)GTBP -99.7% (-75.9%/yr)GTBP compounded faster over this window
Log scale — wide-divergence pair
ACON GTBP
ACON vs GTBP: by the numbers
- •GTBP is the larger company ($8M vs $7M market cap).
- •Both run net losses; GTBP's is the smaller (0.00% vs -10978.48% net margin).
Metrics side by side
Valuation
| Metric | ACON | GTBP |
|---|---|---|
| P/S ratio | 79.48 | N/A |
| P/B ratio | 0.39 | 2.22 |
Profitability
| Metric | ACON | GTBP |
|---|---|---|
| Gross margin | -291.27% | 0.00% |
| Operating margin | -9312.55% | 0.00% |
| Net margin | -10978.48% | 0.00% |
| ROE | -54.09% | -618.74% |
| ROIC | -57.11% | -457.75% |
Growth (annualized)
| Metric | ACON | GTBP |
|---|---|---|
| Revenue CAGR (5Y) | 3.75% | N/A |
| Total return CAGR (5Y) | N/A | -73.13% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.